Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Allovir Has Agreed To Merge With Kalaris Therapeutics In An All-Stock Transaction, After Closing, The Combined Company Is Expected To Operate Under The Name Kalaris Therapeutics And Trade On Nasdaq Under The Ticker Symbol KLRS

Author: Benzinga Newsdesk | November 08, 2024 07:11am

Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris.
Upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company.
Upon closing, the combined company is expected to have approximately $100 million in cash, which is expected to be sufficient to fund the combined company's operating expenses and capital expenditure requirements into the fourth quarter of 2026.

Posted In: ALVR